CXCL8 and congenital rubella syndrome: In CAR-T cell therapy, engineered T cell expansion is usually accompanied by high-grade CRS with elevated circulating levels of interferon (IFN)-γ, granulocyte-colony stimulating factor (G-CSF), IL-6, IL-8, and IL-10.